David Tran, MD, PhD

Associate Professor of Neurological Surgery and Neurology

Division Chief, Neuro-Oncology (Neurological Surgery) and Co-Director of the USC Brain Tumor Center (BTC)

Image of David Tran, MD, PhD
Is this your profile? Click to edit

Overview

Dr Tran received his MD and PhD degrees from the Mayo Clinic College of Medicine in 2005 and completed his postgraduate training in Oncology and Neuro-Oncology at Washington University School of Medicine in St Louis in 2011. He is a leader in Precision Medicine with many seminal publications in cancer research and serves as the principal investigator of several national clinical trials in brain cancer. Research in the Tran laboratory focuses on understanding the molecular mechanism of how cancer develops, progresses, and resists treatment through a vertically integrated approach, starting with clinical observations, guided by systems and computational analyses, followed by experimental validation and translation into novel anti-cancer therapeutics.

Publications

  • A Spatial Interpolation Approach to Assign Magnetic Resonance Imaging-Derived Material Properties for Finite Element Models of Adeno-Associated Virus Infusion Into a Recurrent Brain Tumor J Biomech Eng. 2024 Oct 01; 146(10). . View in PubMed
  • Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors J Neurooncol. 2023 Sep; 164(3):701-710. . View in PubMed
  • Comparison of preoperative versus postoperative treatment dosimetry plans of single-fraction stereotactic radiosurgery for surgically resected brain metastases Neurosurg Focus. 2023 08; 55(2):E9. . View in PubMed
  • Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial JAMA Oncol. 2023 01 01; 9(1):112-121. . View in PubMed
  • The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival J Neurooncol. 2022 Sep; 159(2):479-484. . View in PubMed
  • Tumor Treating Fields: killing two birds with one stone J Clin Invest. 2022 Apr 15; 132(8). . View in PubMed
  • Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma J Clin Invest. 2022 04 15; 132(8). . View in PubMed
  • Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma Neurooncol Adv. 2022; 4(1):vdac042. . View in PubMed
  • Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic Front Oncol. 2021; 11:679702. . View in PubMed
  • In situ vaccination with laser interstitial thermal therapy augments immunotherapy in malignant gliomas J Neurooncol. 2021 Jan; 151(1):85-92. . View in PubMed
  • A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma Neurooncol Adv. 2021; 3(1):vdab164. . View in PubMed
  • A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma Neuro Oncol. 2020 Oct 14; 22(10):1505-1515. . View in PubMed
  • Tumor Treating Fields in the Management of Patients with Malignant Gliomas Curr Treat Options Oncol. 2020 Jul 30; 21(9):76. . View in PubMed
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial Clin Cancer Res. 2020 04 01; 26(7):1586-1594. . View in PubMed
  • A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872 Cancer. 2019 Nov 01; 125(21):3790-3800. . View in PubMed
  • Quantitative characterization of 3D bioprinted structural elements under cell generated forces Nat Commun. 2019 Jul 10; 10(1):3029. . View in PubMed
  • Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity PLoS One. 2019; 14(10):e0223555. . View in PubMed
  • Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma J Neurooncol. 2018 May; 138(1):105-111. . View in PubMed
  • Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma Neuro Oncol. 2018 Mar 27; 20(4):472-483. . View in PubMed
  • Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma J Transl Med. 2018 06 29; 16(1):179. . View in PubMed
  • First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma J Transl Med. 2018 05 29; 16(1):142. . View in PubMed
  • Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial JAMA. 2017 Dec 19; 318(23):2306-2316. . View in PubMed
  • Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors’ reply Lancet Oncol. 2017 12; 18(12):e709-e710. . View in PubMed
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Lancet Oncol. 2017 10; 18(10):1373-1385. . View in PubMed
  • An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma Proc Natl Acad Sci U S A. 2016 Dec 20; 113(51):E8247-E8256. . View in PubMed
  • Molecular and histologic characteristics of pseudoprogression in diffuse gliomas J Neurooncol. 2016 Dec; 130(3):529-533. . View in PubMed
  • A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy J Neurooncol. 2016 Jun; 128(2):259-66. . View in PubMed
  • Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier PLoS One. 2016; 11(2):e0148613. . View in PubMed
  • Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series Case Rep Neurol. 2016; 8(1):1-9. . View in PubMed
  • Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial JAMA. 2015 Dec 15; 314(23):2535-43. . View in PubMed
  • Central Nervous System Cancers, Version 12015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1191-202. . View in PubMed
  • Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):1000-1007. . View in PubMed
  • A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells Cell Rep. 2015 Jun 23; 11(11):1809-21. . View in PubMed
  • Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):268-76. . View in PubMed
  • Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors Dis Markers. 2015; 2015:874904. . View in PubMed
  • Stereotactic laser ablation of high-grade gliomas Neurosurg Focus. 2014 Dec; 37(6):E1. . View in PubMed
  • Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):877-85. . View in PubMed
  • Transient SNAIL1 expression is necessary for metastatic competence in breast cancer Cancer Res. 2014 Nov 01; 74(21):6330-40. . View in PubMed
  • Central nervous system cancers, version 22014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Nov; 12(11):1517-23. . View in PubMed
  • Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe) Semin Oncol. 2014 Oct; 41 Suppl 6:S4-S13. . View in PubMed
  • Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma Semin Oncol. 2014 Jun; 41 Suppl 4:S1-14. . View in PubMed
  • Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas Neuro Oncol. 2014 Jan; 16(1):123-30. . View in PubMed
  • Central nervous system cancers J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1114-51. . View in PubMed
  • Antiangiogenic agents for nonmalignant brain tumors J Neurol Surg B Skull Base. 2013 Jun; 74(3):136-41. . View in PubMed
  • Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence Mol Cancer Res. 2011 Dec; 9(12):1644-57. . View in PubMed
  • CAML loss causes anaphase failure and chromosome missegregation Cell Cycle. 2009 Mar 15; 8(6):940-9. . View in PubMed
  • Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABA(A) receptors Mol Cell Neurosci. 2008 Jun; 38(2):277-89. . View in PubMed
  • CAML is a p56Lck-interacting protein that is required for thymocyte development Immunity. 2005 Aug; 23(2):139-52. . View in PubMed
  • Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro Mol Cell Biol. 2004 Sep; 24(18):8195-209. . View in PubMed
  • CAML is required for efficient EGF receptor recycling Dev Cell. 2003 Aug; 5(2):245-56. . View in PubMed
  • Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest J Biol Chem. 1997 May 09; 272(19):12650-61. . View in PubMed
  • Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression J Biol Chem. 1996 Mar 15; 271(11):6050-61. . View in PubMed